Anti-cancer drugs and their effect on the ubiquitin cycle

• Conditions: cancer; hematologic malignancies; 10024324; 10025320

• Registration Number: NL-OMON31019
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 110

Inclusion Criteria

1. hematologic malignancy
2. treatment with anthracyclins and/or proteasome inhibitors

Exclusion Criteria

prior treatment with either anthracyclins or proteasome inhibition

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To decipher the effect of anthracyclins on the ubiquitin cycle in living cells<br /><br>and to decipher the biological reason for the effect on uH2 by both<br /><br>anthracyclins and proteasome inhibitors, and both drugs in combination.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>For the clinical part of the research project the effect of anthracyclines<br /><br>and/or proteasome inhibitors on histone de-ubiquitination as observed in vivo<br /><br>after administration of these drugs, will be correlated with outcome of the<br /><br>patients (response to treatment and progression-free survival).</p><br>